Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

U.S.-based companies are dragging down the major stock market indexes. But getting caught up in short-term market movements ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering ... on the CRISPR/Cas9 gene-editing technology to be approved towards the end of last year, when it was ...

Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple effect is already being felt across biopharma.